Janssen - The launching pad: exploring the potential of the IL-23 pathway in PsA


Industry room 3
English
Satellite Symposia
03 June 2021 17:30 - 19:00

Learning objectives

After this symposium, participants should be able to:

  • Describe the efficacy and safety data on targeting the IL-23 pathway in psoriatic arthritis and psoriasis, and consider how these data impact clinical practice
  • Analyse how comorbidities, disease severity, and drug safety drive management decisions
  • Identify how the latest therapeutics treat the domains of psoriatic arthritis

Presentations

Title Time Calendar .ics
Welcome and introduction
03 June 2021 17:30 - 17:35 .ics
In it for the long haul: IL-23 pathway inhibition in PsA
03 June 2021 17:35 - 17:50 .ics
Lessons learned from targeting the IL-23 pathway in psoriasis
03 June 2021 17:50 - 18:05 .ics
Why IL-23? PsA pathophysiology through the domains
03 June 2021 18:05 - 18:20 .ics
Panel discussion and Q&A
03 June 2021 18:20 - 18:40 .ics
Close of meeting
03 June 2021 18:40 - 18:45 .ics